U.S. Residential REITs Stock News

NYSE:AAP
NYSE:AAPSpecialty Retail

Advance Auto Parts (AAP) Restructuring Story Keeps Fair Value In Focus

Advance Auto Parts (AAP) is in the middle of a multi year restructuring that targets its operational challenges and competitive pressures. This effort, along with its perceived risks and benefits, is now a central focus for investors. See our latest analysis for Advance Auto Parts. At a recent share price of US$57.80, Advance Auto Parts has seen its 90 day share price return rise 9.84% and its year to date share price return rise 48.62%, while the 1 year total shareholder return is slightly...
NYSE:CNO
NYSE:CNOInsurance

3% Overvalued? CNO Financial Group (CNO) Following Its Dividend And Guidance Update

CNO Financial Group (CNO) has drawn fresh attention after affirming a quarterly cash dividend of $0.18 per share, along with its recent earnings report, upgraded full year guidance and continued share repurchases. See our latest analysis for CNO Financial Group. The recent dividend affirmation and guidance upgrade come after a strong run in CNO Financial Group's stock, with a 90 day share price return of 19.47% and a 1 year total shareholder return of 51.43% that point to strengthening...
NYSE:SPG
NYSE:SPGRetail REITs

Why Simon Property Group (SPG) Is Getting Attention Today

Recent performance snapshot for Simon Property Group stock Simon Property Group (SPG) has drawn investor attention after a period of mixed recent returns, with the stock modestly higher over the past month and past 3 months but lower over the past week. For context, Simon Property Group reports annual revenue of US$6,648.6m and net income of US$4,690.1m from its global portfolio of shopping, dining, entertainment and mixed-use properties, largely concentrated in the United States. See our...
NYSE:SWK
NYSE:SWKMachinery

What’s Behind Stanley Black & Decker (SWK) Shares Climbing Today?

Stanley Black & Decker (SWK) is back in focus after a second quarter that slightly exceeded expectations on organic revenue growth and margins, paired with higher full year earnings guidance and new capital allocation moves. See our latest analysis for Stanley Black & Decker. Investor response to Stanley Black & Decker’s raised earnings guidance and ongoing share repurchases has been reflected in a 30-day share price return of 17.76% and a year-to-date share price return of 35.86%. The 1-year...
NasdaqGS:PGNY
NasdaqGS:PGNYHealthcare

Progyny (PGNY) Faces A Valuation Test After Earnings, Guidance, And A Buyback

Progyny (PGNY) is back in focus after its latest quarterly update on August 6, 2026. The company reported second quarter and first half results, issued fresh guidance, and completed a share repurchase tranche. See our latest analysis for Progyny. The share price reaction around the August 6 earnings release has been weak, with a 1-day share price return of down 6.98% and a 7-day move of down 10.88%. At the same time, a 90-day share price return of 19.83% and a 1-year total shareholder return...
NasdaqGS:SBAC
NasdaqGS:SBACSpecialized REITs

Is SBA Communications (SBAC) Undervalued Following Its Earnings And Guidance Update?

SBA Communications (SBAC) has released a busy August update, combining its second quarter and six-month results with refreshed 2026 guidance, a quarterly dividend affirmation, and a buyback progress report. See our latest analysis for SBA Communications. The fresh earnings, guidance and dividend update arrives after a weaker share price patch, with SBA Communications posting a 90 day share price return that fell 15.29% and a 1 year total shareholder return that declined 14.71%, which signals...
NYSE:PBF
NYSE:PBFOil and Gas

PBF Energy (PBF) Draws Fresh Attention After Q2, Is It Still Cheap?

Why PBF Energy is back in focus after Q2 results PBF Energy (PBF) is drawing increased attention after its second quarter 2026 update combined several key developments for shareholders. The company reported stronger sales and earnings, confirmed its dividend, and issued fresh throughput guidance. The quarter featured unaudited production and throughput figures that were higher than the same period a year earlier across the portfolio. Management also outlined expected third quarter throughput...
NasdaqGS:WMG
NasdaqGS:WMGEntertainment

Warner Music Group (WMG) Is Up 5.1% After Q3 Earnings Beat And Steady Dividend Payout

Warner Music Group reported past third-quarter 2026 results showing sales of US$1,864 million and net income of US$204 million, alongside a regular quarterly dividend of US$0.20 per share payable on September 1, 2026. These results, combined with a higher year-to-date net income and a maintained dividend, suggest management is prioritizing both earnings quality and ongoing cash returns to shareholders. Next, we’ll examine how Warner Music Group’s stronger profitability profile may influence...
NasdaqGS:DDOG
NasdaqGS:DDOGSoftware

Datadog (DDOG) Moved, What Is Behind The Fresh Attention?

Datadog (DDOG) is back in focus after its largest customer, a leading AI company, renewed its contract while reducing usage. This shift fed directly into softer sequential growth guidance despite a strong quarter. See our latest analysis for Datadog. Datadog’s share price has been volatile around the earnings release and contract news, with a 7 day share price return down 14.5% and a 30 day share price return down 9.17%. However, the year to date share price return of 74.87% and 1 year total...
NasdaqGS:TARS
NasdaqGS:TARSPharmaceuticals

Tarsus Pharmaceuticals (TARS) Lifts XDEMVY Guidance Following Earnings But Is The Stock Already Priced In

How Tarsus Pharmaceuticals’ latest earnings and guidance updates shape the stock debate Tarsus Pharmaceuticals (TARS) reported second quarter 2026 revenue of $173.91 million and a net loss of $18.55 million, alongside higher full year XDEMVY sales guidance that gives investors fresh numbers to assess. For the first half of 2026, Tarsus Pharmaceuticals reported revenue of $335.97 million. The company also reported a net loss of $25.52 million for the same period, which included basic loss per...
NasdaqGS:PRAX
NasdaqGS:PRAXBiotechs

Can Praxis Precision Medicines' (PRAX) Extended Cash Runway Offset Mounting Losses In Its CNS Pipeline Push?

Praxis Precision Medicines recently reported its second-quarter 2026 results, posting a net loss of US$83.72 million and basic loss per share from continuing operations of US$2.87, while six-month losses reached US$176.28 million with a basic loss per share of US$6.08. Despite the larger losses, management highlighted continued progress on late-stage central nervous system drug candidates and reiterated that its cash resources are expected to fund operations into 2028, placing near-term...
NasdaqCM:PRCH
NasdaqCM:PRCHInsurance

Porch Group (PRCH) After Strong Q2 And Higher Guidance, Is The Valuation Case Stronger?

Porch Group (PRCH) is back in focus after a strong Q2 2026, with higher sales, positive net income, and improved Insurance Services leading management to raise full year revenue and adjusted EBITDA guidance. See our latest analysis for Porch Group. The earnings surprise and upgraded 2026 guidance appear to be feeding into stronger momentum for Porch Group, with a 30 day share price return of 6.73% and a 90 day share price return of 53.44%. That sits alongside a year to date share price return...
NasdaqGS:UCTT
NasdaqGS:UCTTSemiconductor

Ultra Clean Holdings (UCTT) Could Be 36% Undervalued On Second Quarter Earnings

Why Ultra Clean Holdings Stock Is Back On Investors’ Radar Ultra Clean Holdings (UCTT) has drawn attention after reporting second quarter 2026 results and issuing fresh guidance for the third quarter. The new numbers give investors updated reference points on revenue, earnings and valuation. See our latest analysis for Ultra Clean Holdings. Ultra Clean Holdings' recent second quarter earnings and new third quarter guidance have arrived after a sharp run in the share price, with a year to date...
NasdaqCM:CLDX
NasdaqCM:CLDXBiotechs

Why Celldex Therapeutics (CLDX) Is Up 10.7% After Wider Losses And Barzolvolimab Phase 3 Progress

Earlier this week, Celldex Therapeutics reported its second quarter 2026 results, showing revenue of just US$22,000 and a net loss of US$73.5 million, alongside a wider first-half loss of US$152.19 million. At the same time, the company updated investors on its clinical pipeline, highlighting positive Phase 1 data for bispecific antibody CDX-622 and continued progress of barzolvolimab into late-stage studies despite discontinuing a prurigo nodularis program. Next, we’ll examine how the...
NYSE:MTRN
NYSE:MTRNMetals and Mining

Materion (MTRN) Could Be 22% Undervalued Following Record Q2 Results

Why Materion Stock Is Back On Investors’ Radar Materion (MTRN) moved into focus after reporting record second quarter value added sales and adjusted earnings per share, alongside a higher 2026 outlook that highlighted firm demand in key end markets. See our latest analysis for Materion. The latest earnings beat and higher 2026 outlook have been reflected in Materion’s share price, with a 7 day share price return of 35.71% and year to date share price return of 125.67%. Over the longer term,...